- |||||||||| Review, Journal: Pharmacological treatment of COVID-19: an opinion paper. (Pubmed Central) - Mar 18, 2022
The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.
- |||||||||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Journal: Novel Nitrile Peptidomimetics for Treating COVID-19. (Pubmed Central) - Mar 17, 2022 On December 22, 2021, the U.S. FDA granted Emergency Use Authorization for the oral viral main protease inhibitor, Nirmatrelvir, to treat patients with mild-to-moderate COVID-19. This patent review reveals the structure-activity relationship of key inhibitors described in the patent WO 2021/250648 A1.
- |||||||||| Paxlovid (nirmatrelvir and ritonavir) / Pfizer
Journal: Association nirmatrelvir/ritonavir contre la COVID-19. (Pubmed Central) - Mar 16, 2022 This patent review reveals the structure-activity relationship of key inhibitors described in the patent WO 2021/250648 A1. No abstract available
|